Supreme Court Shuns Pfizer Appeal in Neurontin Cases

, The Litigation Daily

The high court declined on Monday to take up Pfizer Inc.'s challenge to a $142 million jury verdict and continued litigation stemming from the company's off-label marketing of the epilepsy drug Neurontin.